IL148068A0 - TREATMENT OF MIGRAINE BY ADMINISTRATION OF α-LUPOIC ACID OR DERIVATIVES THEREOF - Google Patents

TREATMENT OF MIGRAINE BY ADMINISTRATION OF α-LUPOIC ACID OR DERIVATIVES THEREOF

Info

Publication number
IL148068A0
IL148068A0 IL14806800A IL14806800A IL148068A0 IL 148068 A0 IL148068 A0 IL 148068A0 IL 14806800 A IL14806800 A IL 14806800A IL 14806800 A IL14806800 A IL 14806800A IL 148068 A0 IL148068 A0 IL 148068A0
Authority
IL
Israel
Prior art keywords
migraine
treatment
acid
lupoic
administration
Prior art date
Application number
IL14806800A
Other languages
English (en)
Original Assignee
Asta Medica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Asta Medica Ag filed Critical Asta Medica Ag
Publication of IL148068A0 publication Critical patent/IL148068A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/385—Heterocyclic compounds having sulfur as a ring hetero atom having two or more sulfur atoms in the same ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL14806800A 1999-08-30 2000-08-26 TREATMENT OF MIGRAINE BY ADMINISTRATION OF α-LUPOIC ACID OR DERIVATIVES THEREOF IL148068A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19941217A DE19941217A1 (de) 1999-08-30 1999-08-30 Behandlung der Migräne durch Verabreichung von alpha-Liponsäure oder Derivaten derselben
PCT/EP2000/008315 WO2001015693A2 (de) 1999-08-30 2000-08-26 BEHANDLUNG DER MIGRÄNE DURCH VERABREICHUNG VON α-LIPONSÄURE ODER DERIVATEN DERSELBEN

Publications (1)

Publication Number Publication Date
IL148068A0 true IL148068A0 (en) 2002-09-12

Family

ID=7920152

Family Applications (2)

Application Number Title Priority Date Filing Date
IL14806800A IL148068A0 (en) 1999-08-30 2000-08-26 TREATMENT OF MIGRAINE BY ADMINISTRATION OF α-LUPOIC ACID OR DERIVATIVES THEREOF
IL148068A IL148068A (en) 1999-08-30 2002-02-06 Use of alpha-lipoic acid or its derivatives as an active ingredient in drugs for the treatment or prevention of migraine

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL148068A IL148068A (en) 1999-08-30 2002-02-06 Use of alpha-lipoic acid or its derivatives as an active ingredient in drugs for the treatment or prevention of migraine

Country Status (32)

Country Link
US (1) US6251935B1 (ru)
EP (1) EP1207878B1 (ru)
JP (1) JP4773015B2 (ru)
KR (1) KR100624215B1 (ru)
CN (1) CN1170535C (ru)
AT (1) ATE232725T1 (ru)
AU (1) AU781505B2 (ru)
BG (1) BG65735B1 (ru)
BR (1) BR0013651A (ru)
CA (1) CA2382548C (ru)
CZ (1) CZ301789B6 (ru)
DE (2) DE19941217A1 (ru)
DK (1) DK1207878T3 (ru)
EE (1) EE04869B1 (ru)
ES (1) ES2190985T3 (ru)
HK (1) HK1046637A1 (ru)
HR (1) HRP20020168A2 (ru)
HU (1) HU229603B1 (ru)
IL (2) IL148068A0 (ru)
IS (1) IS2214B (ru)
MX (1) MXPA02002246A (ru)
NO (1) NO328692B1 (ru)
NZ (1) NZ517276A (ru)
PL (1) PL200928B1 (ru)
PT (1) PT1207878E (ru)
RS (1) RS50139B (ru)
RU (1) RU2232577C2 (ru)
SK (1) SK286260B6 (ru)
TR (1) TR200200461T2 (ru)
UA (1) UA71031C2 (ru)
WO (1) WO2001015693A2 (ru)
ZA (1) ZA200201637B (ru)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2352144A1 (en) * 1998-11-25 2000-06-02 Yissum Research Development Company Of The Hebrew University In Jerusale M Scavenger compounds
US7030154B2 (en) 2002-06-07 2006-04-18 Juvenon, Inc. Stability of lipoic acid
US20050065094A1 (en) 2003-09-05 2005-03-24 Boehringer Ingelheim International Gmbh Use of telmisartan for the prevention and treatment of vascular headache
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
US20090054513A1 (en) * 2007-08-22 2009-02-26 Response Scientific, Inc. Method of managing blood glucose levels, insulin levels and/or insulin receptor functionality in individuals with diabetes, polycystic ovarian syndrome and/or alzheimer's disease
US7943163B2 (en) 2007-08-22 2011-05-17 Response Scientific, Inc. Medical food or nutritional supplement, method of manufacturing same, and method of managing diabetes
KR101493125B1 (ko) 2008-11-24 2015-02-12 세다르스-신나이 메디칼 센터 항산화성 캠토테신 유도체 및 이들의 항산화성 항종양성 나노구체
EP2429991B1 (en) 2009-05-15 2014-09-10 Redx Pharma Limited Redox drug derivatives
KR100935554B1 (ko) 2009-06-24 2010-01-07 주식회사 셀트리온제약 피페라진 다이티옥트산염 및 이를 포함하는 약제학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU620265A1 (ru) * 1977-02-21 1978-08-25 Центральный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Курортологии И Физиотерапии Способ лечени атеросклероза сосудов головного мозга и гипертонической болезни
ES2043897T3 (es) * 1988-01-28 1994-01-01 Koeltringer Peter Preparado de combinacion, en especial para el tratamiento de enfermedades de las celulas nerviosas.
JPH03169813A (ja) * 1989-11-09 1991-07-23 Asta Pharma Ag 細胞保護作用を有する疼痛及び炎症性疾患及び／又はレトロウイルスに起因する病気の治療用医薬並びにその製法
US5569670A (en) * 1992-06-05 1996-10-29 Asta Medica Aktiengesellschaft Combination medications containing alpha-lipoic acid and related
DE4218572A1 (de) * 1992-06-05 1993-12-09 Asta Medica Ag Synergistische Kombination von Arzneimitteln enthaltend als Wirkstoff alpha-Liponsäure, Dihydroliponsäure, deren Metaboliten sowie die oxidierten und reduzierten Enantiomere der alpha-Liponsäure wie die R-alpha-Liponsäure oder S-alpha-Liponsäure sowie Metaboliten der alpha-Liponsäure mit den Vitaminen A, B1-6, B12, C und E
DE69331727D1 (de) * 1992-06-30 2002-04-25 Howard K Shapiro Verwendung einer kombination bestehend aus einem aminderivat oder aminverwandten derivat der benzoesäure und einem amino-polysaccharide zur herstellung eines medikaments fuer die behandlung von entzündlichen erkrankungen
DE4327426A1 (de) * 1993-08-14 1995-02-16 F H Erdaussiebung Gmbh Anbaugerät zum Sieben und Verfüllen von Erdmaterialien
DE4327462A1 (de) * 1993-08-16 1995-02-23 Carl Heinrich Dr Weischer Neue N-Acetyl-p-Aminophenol-Derivate zur Bekämpfung von Schmerzzuständen
DE4331168A1 (de) * 1993-09-14 1995-03-16 Carl Heinrich Dr Weischer Kombination von N-Acetyl-p-Aminophenol mit schwefelenthaltenden Carbonsäuren, wie z. B. alpha-Liponsäure und deren Derivate, zur Bekämpfung von Schmerzzuständen
EP0855396A1 (en) * 1997-01-22 1998-07-29 ASTA Medica Aktiengesellschaft Thioctic acid metabolites and methods of use thereof
IL123887A0 (en) * 1997-04-02 1998-10-30 Sankyo Co Dithiolan derivatives their use and pharmaceutical compositions containing the same
AU8768098A (en) * 1997-08-04 1999-02-22 Christopher J. Berry Method of treating disease using a tocotrienol and alpha-lipoic acid r derivatives or an ester thereof
GB2333757B (en) * 1998-02-03 2001-06-27 Cheung Kwok Chung Sliding platform
EP1065931A4 (en) * 1998-04-02 2006-10-11 Avicena Group Inc COMPOSITIONS CONTAINING CREATINE COMBINED WITH A SECOND AGENT
AR042572A1 (es) * 1999-04-02 2005-06-29 Sod Conseils Rech Applic Derivados de acido lipoico, procedimiento para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y utilizacion de dichos derivados para la preparacion de los referidos medicamentos

Also Published As

Publication number Publication date
BG65735B1 (bg) 2009-09-30
AU781505B2 (en) 2005-05-26
IL148068A (en) 2007-06-03
NO328692B1 (no) 2010-04-26
TR200200461T2 (tr) 2002-08-21
EP1207878A2 (de) 2002-05-29
RU2232577C2 (ru) 2004-07-20
IS6284A (is) 2002-02-26
NO20020917D0 (no) 2002-02-25
EE04869B1 (et) 2007-08-15
PL352741A1 (en) 2003-09-08
YU15002A (sh) 2005-03-15
IS2214B (is) 2007-03-15
CA2382548C (en) 2007-07-03
ATE232725T1 (de) 2003-03-15
WO2001015693A2 (de) 2001-03-08
BG106407A (en) 2002-10-31
CN1170535C (zh) 2004-10-13
NO20020917L (no) 2002-02-25
CA2382548A1 (en) 2001-03-08
SK286260B6 (sk) 2008-06-06
HK1046637A1 (en) 2003-01-24
PL200928B1 (pl) 2009-02-27
SK2902002A3 (en) 2002-09-10
BR0013651A (pt) 2002-05-07
PT1207878E (pt) 2003-07-31
CN1371280A (zh) 2002-09-25
DK1207878T3 (da) 2003-06-16
EE200200098A (et) 2003-04-15
ES2190985T3 (es) 2003-09-01
RS50139B (sr) 2009-03-25
UA71031C2 (ru) 2004-11-15
CZ2002655A3 (cs) 2002-07-17
HUP0203025A3 (en) 2004-12-28
WO2001015693A3 (de) 2001-12-20
DE19941217A1 (de) 2001-03-15
US6251935B1 (en) 2001-06-26
ZA200201637B (en) 2003-01-29
CZ301789B6 (cs) 2010-06-23
KR20020060168A (ko) 2002-07-16
JP2003508438A (ja) 2003-03-04
DE50001301D1 (de) 2003-03-27
HU229603B1 (en) 2014-02-28
NZ517276A (en) 2004-06-25
AU7279900A (en) 2001-03-26
KR100624215B1 (ko) 2006-09-18
MXPA02002246A (es) 2003-08-20
HUP0203025A2 (hu) 2002-12-28
HRP20020168A2 (en) 2003-06-30
EP1207878B1 (de) 2003-02-19
JP4773015B2 (ja) 2011-09-14

Similar Documents

Publication Publication Date Title
MY130441A (en) Solutions containing epinastin
PL350456A1 (en) N−cyanomethylamides as protease inhibitors
MXPA05002871A (es) Derivados de benzodiazaepina y composiciones farmaceuticas que los contienen.
CA2445145A1 (en) Carboxylic acid substituted oxazole derivatives for use as ppar-alpha and -gamma activators in the treatment of diabetes
NZ524138A (en) Cyanophenoxy carboxylic acid compounds and compositions for delivering active agents
HK1046374B (zh) 喜樹碱類似物及其製備方法
RS54050B1 (en) FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS
IL148068A0 (en) TREATMENT OF MIGRAINE BY ADMINISTRATION OF α-LUPOIC ACID OR DERIVATIVES THEREOF
EP1192949A4 (en) PREVENTIVE OR THERAPEUTIC DRUGS FOR TREATING FIBROSIS AND CONTAINING CHYMASE INHIBITORS AS ACTIVE INGREDIENTS
MXPA02012182A (es) Medicamentos para la terapia de demencias.
EE05241B1 (et) Distamtsiini a-halogenoakrlolderivaadi kasutamine
WO2002009717A1 (fr) Remedes contre la dyserection contenant des derives de prostaglandine comme principe actif
EP1219296A4 (en) SEBUM PRODUCTION INHIBITORS
MXPA05008711A (es) Uso de r-10-hidroxi-10,11-dihidro-carbamazepina en dolor neuropatico.
AR026435A1 (es) Procedimiento para la administracion simplificada del acido alfa-lipoico, o de derivados del mismo y el procedimiento para preparar la composicionfarmaceutica o nutricional de aplicacion en dicho metodo
EP1452522A3 (en) Novel compounds and compositions as protease inhibitors
WO2000003699A3 (de) Arzneimittel mit einem gehalt an phosphonsäurederivaten als wirkstoff und ihre verwendung

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed